Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Para-Methoxyamphetamine SCHEMBL394418 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| Para-Methoxyamphetamine SCHEMBL264634 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| Para-Methoxyamphetamine SCHEMBL7253563 | 0.98 | SLC6A4 (0.96) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| Para-Methoxyamphetamine SCHEMBL10975159 | 0.98 | SLC6A4 (0.96) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL9468376 | 0.94 | SLC6A4 (0.89) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL9468512 | 0.94 | SLC6A4 (0.89) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL6540600 | 0.86 | SLC6A4 (0.74) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL7528408 | 0.84 | SLC6A4 (0.73) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL656814 | 0.84 | SLC6A4 (0.73) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL10774940 | 0.84 | SLC6A4 (0.73) | SLC6A4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| US-20210137854-A1 | TAAR Receptor Agonists for the Treatment of Alopecia | JUPITER WELLNESS INC. | 2021-05-13 | — | — | US | claimed |
| WO-2020023084-A1 | TAAR RECEPTOR AGONISTS FOR THE TREATMENT OF ALOPECIA | APPLIED BIOLOGY, INC. (US) | 2020-01-30 | — | — | WO | claimed |
| US-9435816-B2 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods of their preparation and their use | CHIRON AS (NO) | 2016-09-06 | — | — | US | claimed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140288454-A1 | Method For Using Exhaled Breath to Determine the Presence of Drug | Pulmonary Analytics (US) | 2014-09-25 | — | — | US | claimed |
| US-20140227792-A1 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON A/S (NO) | 2014-08-14 | — | — | US | claimed |
| WO-2013014287-A2 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON AS (NO) | 2013-01-31 | — | — | WO | claimed |
| EP-2551675-A1 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use | Chiron AS (NO) | 2013-01-30 | — | — | EP | claimed |
| US-20060148046-A1 | Enzymatic process for the preparation of an intermediate compound and use thereof for the synthesis of tamsulosin hydrochloride | QUIMICA SINTETICA, S.A. | 2006-07-06 | — | — | US | claimed |
| WO-2006070285-A2 | ENZYMATIC PREPARATION OF AN INTERMEDIATE COMPOUND FOR THE SYNTHESIS OF TAMSULOSIN | QUIMICA SINTETICA, S.A. (ES) | 2006-07-06 | — | — | WO | claimed |
| WO-2026106796-A1 | SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS | FOLLEA INTERNATIONAL (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INT (US) | 2026-02-12 | — | — | US | disclosed |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | Pharmapotheca A, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| US-5508199-A | A CLONED CDNA ENCODING DEBRISOQUINE 4-HYDROXYLASE GENE; PROBES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-04-16 | — | — | US | disclosed |
| EP-0255728-B1 | PHENOXYACETIC ACID COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE | TANABE SEIYAKU CO., LTD. (JP) | 1991-11-27 | — | — | EP | disclosed |
| US-4866196-A | ANTICOAGULANTS | TANABE SEIYAKU CO., LTD. (JP) | 1989-09-12 | — | — | US | disclosed |
| EP-0255728-A2 | Phenoxyacetic acid compounds, their preparation, pharmaceutical composition and use | TANABE SEIYAKU CO., LTD. (JP) | 1988-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227792-A1 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | PNMT, HTR2C, HTR2A | SLC6A4 50/4885CYP1A2 59/4885CYP2D6 38/4885 |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | SMS, SRMS, SRM | SLC6A4 14/4885CYP1A2 1411/4885CYP2D6 387/4885 |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | DYRK4, DYRK2, STRA6 | SLC6A4 56/4885CYP1A2 3368/4885CYP2D6 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.